Vertex Pharmaceuticals shares are trading higher after the company announced results from its Phase 3 program of VX-548 in moderate-to-severe acute pain. The stock initially fell on the data and has since rebounded.

Vertex Pharmaceuticals Incorporated -2.01%

Vertex Pharmaceuticals Incorporated

VRTX

447.75

-2.01%

Vertex Pharmaceuticals shares are trading higher after the company announced results from its Phase 3 program of VX-548 in moderate-to-severe acute pain. The stock initially fell on the data and has since rebounded.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via